Amundi’s BioCryst Pharmaceuticals BCRX Stock Holding History

Amundi’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,471	Closed	-$106K	–	1904
2022 Q3	$106K	Hold	7,471	–	–	﹤0.01%	1547
2022 Q2	$86K	Buy	+7,471	New	+$77.1K	﹤0.01%	1473

Other funds holding BCRX

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Amundi's BCRX Position: Q4 2022 in Review

Amundi sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 7,471 shares — an estimated $106K sold.

Amundi first reported a position in BCRX in Q2 2022 and held it in 2 quarters. The position peaked at $106K in Q3 2022. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

Amundi reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Amundi sold 7,471 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $106K.
Amundi first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Amundi's BioCryst Pharmaceuticals position peaked at $106K in Q3 2022.
230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on Amundi's 13F filing for Q4 2022, filed 14 Feb 2023.